Antiproliferative effect of ferrocifen drug candidates on malignant pleural mesothelioma cell lines

Inorganica Chimica Acta

Volumn 362, Issue 11, 2009, Pages 4037-4042

  Zanellato, Ilaria ^a   Heldt, Jan Martin ^b   Vessières, Anne ^b   Jaouen, Gérard ^b   Osella, Domenico ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b PSL RESEARCH UNIVERSITY   (France)

Author keywords

Antiproliferative activity; Bio orgometallic chemistry; Ferrocifens; Malignant mesothelioma

Indexed keywords

ALKALINITY; CELL CULTURE; CELL PROLIFERATION; ELECTROPHORESIS; ORGANOMETALLICS; TUMORS;

ANTI-PROLIFERATIVE ACTIVITIES; ANTIPROLIFERATIVE EFFECT; CELL VIABILITY ASSAYS; DIFFERENT MECHANISMS; FERROCIFENS; MALIGNANT MESOTHELIOMA; MALIGNANT PLEURAL MESOTHELIOMAS; SINGLE CELL GEL ELECTROPHORESIS;

CELLS;

EID: 67849116719     PISSN: 00201693     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ica.2009.05.047     Document Type: Article

References (44)

1. Pass H.I., Vogelzang N.J., and Carbone M. Malignant Mesothelioma, Advances in Pathogenesis, Diagnosis, and Translational Therapies (2005), Springer, New York
2. Wagner J.C., Sleggs C.A., and Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Brit. J. Ind. Med. 17 (1960) 260
3. Selikoff I.J., Churg J., and Hammond E.C. The occurrence of asbestosis among insulation workers in the United States. Ann. NY Acad. Sci. 132 1 (1965) 139
4. Moore A.J., Parker R., and Wiggins J. Malignant mesothelioma. Orphanet. J. Rare Dis. (2008) 3
5. Adams V.I., Unni K.K., Muhm J.R., Jett J.R., Ilstrup D.M., and Bernatz P.E. Diffuse malignant mesothelioma of the pleura. Diagnosis and survival in 92 cases. Cancer 58 7 (1986) 1540
6. Gerwin B.I., Lechner J.F., Reddel R.R., Roberts A.B., Robbins K.C., Gabrielson E.W., and Harris C.C. Comparison of production of transforming growth factor-b and platelet-derived growth factor by normal human mesothelial cells and mesothelioma cell lines. Cancer Res. 47 (1987) 6180
7. Manning L.S., Whitaker D., Murch A.R., Garlepp M.J., Davis M.R., Musk A.W., and Robinson B.W. Establishment and characterization of five human malignant mesothelioma cell lines derived from pleural effusions. Int. J. Cancer 47 (1991) 285
8. Kent M., Rice D., and Flores R. Diagnosis, staging and surgical treatment of malignant pleural mesothelioma. Curr. Treat. Options Oncol. 9 2-3 (2008) 158
9. Kindler H.L. Systemic treatments for mesothelioma: standard and novel. Curr. Treat. Options Oncol. 9 2-3 (2008) 171
10. Berghmans T., Paesmans M., Lalami Y., Louviaux I., Luce S., Mascaux C., Meert A.P., and Sculier J.P. Activity of chemotherapy and immunotherapy on malignant mesothelioma. Lung Cancer 38 (2002) 111
11. Top S., Vessieres A., Cabestaing C., Laios J., Leclercq G., Provot C., and Jaouen G. Studies on organometallic selective estrogen receptor modulators (SERMs). Dual activity in the hydroxy-ferrocifen series. J. Organomet. Chem. 637-639 (2001) 500
12. Top S., Vessières A., Leclercq G., Quivy J., Tang J., Vaissermann J., Huché M., and Jaouen G. Synthesis, biochemical properties and molecular modelling studies of organometallic specific estrogen receptor modulators (SERMs), the ferrocifens and hydroxyferrocifens: evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormone-independent breast cancer cell lines. Chem. Eur. J. (2003) 5223
13. Vessières A., Top S., Pigeon P., Hillard E., Boubeker L., Spera D., and Jaouen G. Modification of the estrogenic properties of diphenols by the incorporation of ferrocene. Generation of antiproliferative effects in vitro. J. Med. Chem. 48 (2005) 3937
14. Jaouen G., Top S., and Vessieresin A. In: Jaouen G. (Ed). Bioorganometallics (2006), Wiley-VCH, Weinheim
15. Michard Q., Jaouen G., Vessieres A., and Bernard B.A. Evaluation of cytotoxic properties of organometallic ferrocifens on melanocytes, primary and metastatic melanoma cell lines. J. Inorg. Biochem. 102 (2008) 1980
16. Osella D., Ferrali M., Zanello P., Laschi F., and Fontani M. On the mechanism of the antitumor activity of ferrocenium derivatives. Inorg. Chim. Acta 306 (2000) 42
17. Tabbi G., Cassino C., Cavigiolio G., Colangelo D., Ghiglia A., and Osella D. Water stability and cytotoxic activity relationship of a series of ferrocenium derivatives. ESR insights on the radical production during the degradation process. J. Med. Chem. 45 (2002) 5786
18. Tabbi G., Cassino C., Cavigiolio G., Colangelo D., Ghiglia A.L., Viano I., and Osella D. ESR insights on the radical production during the degradation process relationship of some ferrocenium derivatives. Determination of their water stability and cytotoxic activity. Free Radical Bio. Med. 33 Suppl 1 (2002) 40
19. Osella D., Mahboobi H., Colangelo D., Cavigiolio G., and Vessieres A. FACS analysis of oxidative stress induced on tumour cells by SERMs. Inorg. Chim. Acta (2005) 1993
20. Neuse E.W. Macromolecular ferrocene compounds as cancer drug models. J. Inorg. Organomet. Polym. Mater. 15 1 (2005) 3
21. Cable E.E., Connor J.R., and Isom H.C. Accumulation of iron by primary rat hepatocytes in long-term culture: changes in nuclear shape mediated by non-transferrin-bound forms of iron. Am. J. Pathol. 152 3 (1998) 781
22. E.A. Hillard, P. Pigeon, A. Vessieres, C. Amatore, G. Jaouen, The influence of phenolic hydroxy substitution on the electron transfer and anti-cancer properties of compounds based on the 2-ferrocenyl-1-phenyl-but-1-ene motif, Dalton Trans. (2007) 5073.
23. Fan P.W., and Bolton J.L. Bioactivation of tamoxifen to metabolite E quinone methide: reaction with glutathione and DNA. Drug Metab. Dispos. 29 6 (2001) 891
24. Toma S., Colucci L., Scarabelli L., Scaramuccia A., Emionite L., Betta P.G., and Mutti L. Synergistic effect of the anti-HER-2/neu antibody and cisplatin in immortalized and primary mesothelioma cell lines. J. Cell Physiol. 193 1 (2002) 37
25. Orecchia S., Schillaci F., Salvio M., Libener R., and Betta P.G. Aberrant E-cadherin and gamma-catenin expression in malignant mesothelioma and its diagnostic and biological relevance. Lung Cancer 45S (2004) S37
26. Sigalotti L., Coral S., Altomonte M., Natali L., Gaudino G., Cacciotti P., Libener R., Colizzi F., Vianale G., Martini F., Tognon F., Jungbluth A., Cebon J., Maraskovsky E., Mutti L., and Maio M. Cancer testis antigens expression in mesothelioma. Brit. J. Cancer 86 (2002) 979
27. Fichtinger-Schepman A.M., van der Veer J.L., den Hartog J.H., Lohman P.H., and Reedijk J. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry 24 3 (1985) 707
28. Chaney S.G., and Sancar A. DNA repair: enzymatic mechanisms and relevance to drug response. J. Natl. Cancer Inst. 88 19 (1996) 346
29. S.G. Chaney, A. Sancar, DNA repair: enzymatic mechanisms and relevance to drug response, J. Natl. Cancer Inst. 88 (19) (1996) 346.
30. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano M.D., Fujimoto E.K., Goeke N.M., Olson B.J., and Klenk D.C. Measurement of protein using bicinchoninic acid. Anal. Biochem. 150 1 (1985) 76
31. Trupiano J.K., Geisinger K.R., Willingham M.C., Manders P., Zbieranski N., Case D., and Levine E.A. Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers. Mod. Pathol. 17 (2004) 476
32. Letterie G.S., and Yon J.L. The antiestrogen tamoxifen in the treatment of recurrent benign cystic mesothelioma. Gynecol. Oncol. 70 (1998) 131
33. Ordóñez N.G. Value of estrogen and progesterone receptor immunostaining in distinguishing between peritoneal mesotheliomas and serous carcinomas. Human Pathol. 36 (2005) 1163
34. Welshons W.V., Wolf M.F., Murphy C.S., and Jordan V.C. Estrogenic activity of phenol red. Mol. Cell Endocrinol. 57 3 (1998) 169
35. Moreno-Cuevas J.E., and Sirbasku D.A. Estrogen mitogenic action. III. Is phenol red a "red herring"?. In Vitro Cell Dev. Biol. Anim. 36 7 (2000) 447
36. McKelvey-Martin V.J., Green M.H., Schmezer P., Pool-Zobel B.L., De Méo M.P., and Collins A. The single cell gel electrophoresis assay (Comet assay): a European review. Mutat. Res. 288 (1993) 47
37. Widlak P., and Garrard W.T. Roles of the major apoptotic nuclease-DNA fragmentation factor-in biology and disease. Cell Mol. Life Sci. 66 2 (2009) 263
38. Vanlangenakker N., Berghe T.V., Krysko D.V., Festjens N., and Vandenabeele P. Molecular mechanisms and pathophysiology of necrotic cell death. Curr. Mol. Med. 8 3 (2008) 207
39. Schou K.B., Schneider L., Christensen S.T., and Hoffmann E.K. Early-stage apoptosis is associated with DNA-damage-independent ATM phosphorylation and chromatin decondensation in NIH3T3 fibroblasts. Cell Biol. Int. 32 1 (2008) 107
40. Kastan M.B., Onyekwere O., Sidransky D., Vogelstein B., and Craig R.W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51 (1991) 6304
41. Tishler R.B., Calderwood S.K., Coleman C.N., and Price B.D. Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents. Cancer Res. 5 (1993) 2212
42. Schmitt E., Paquet C., Beauchemin M., and Bertrand R. DNA-damage response network at the crossroads of cell-cycle checkpoints, cellular senescence and apoptosis. J. Zhejiang Univ. Sci. B 8 6 (2007) 377
43. Vazquez A., Bond E.E., Levine A.J., and Bond G.L. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat. Rev. Drug Discov. 7 12 (2008) 979
44. Reiss M., Brash D.E., Muñoz-Antonia T., Simon J.A., Ziegler A., Vellucci V.F., and Zhou Z.L. Status of the p53 tumor suppressor gene in human squamous carcinoma cell lines. Oncol. Res. 4 8-9 (1992) 349